EraGen Biosciences develops, manufactures, and markets molecular reagents. The company’s in-market and pipeline products, based on its patented MultiCode® platform chemistry, are next-generation DNA- and RNA-based tests for the early detection of infectious diseases and genetic-based conditions.
Luminex Corporation today announced a definitive agreement to acquire privately-held EraGen Biosciences, Inc., an innovator in molecular diagnostic testing technologies for infectious disease and genetic applications. The acquisition of EraGen Biosciences provides Luminex with access to a highly complementary portfolio of molecular diagnostic assays based on an innovative and proprietary technology platform called MultiCode®. This unique assay chemistry is a flexible platform for both real-time polymerase chain reaction (PCR) and multiplex PCR-based applications.